Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUNDSystemic administration of adeno-associated virus (AAV) can trigger life-threatening inflammatory responses, including thrombotic microangiopathy (TMA), acute kidney injury due to atypical hemolytic uremic syndrome-like complement activation, immune-mediated myocardial inflammation, and hepatic toxicity.METHODSWe describe the kinetics of immune activation following systemic AAV serotype 9 (AAV9) administration in 38 individuals following 2 distinct prophylactic immunomodulation regimens. Group 1 received corticosteroids and Group 2 received rituximab plus sirolimus in addition to steroids to prevent anti-AAV antibody formation.RESULTSGroup 1 participants had a rapid increase in immunoglobulin M (IgM) and IgG. Increase in D-dimer, decline in platelet count, and complement activation are indicative of TMA. All Group 1 participants demonstrated activation of both classical and alternative complement pathways, as indicated by depleted C4 and elevated soluble C5b-9, Ba, and Bb antigens. Group 2 patients did not have a significant change in IgM or IgG and had minimal complement activation.CONCLUSIONSThis study demonstrates that TMA in the setting of AAV gene therapy is antibody dependent (classical pathway) and amplified by the alternative complement pathway. Critical time points and interventions are identified to allow for management of immune-mediated events that impact the safety and efficacy of systemic gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, levels of complement proteins associated with classical (C3a, C4a, C5a) and alternative (Ba, Bb) pathways along with terminal complement complex SC5b-9 were found to be elevated in patients who only received corticosteroids.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies in patients with Duchenne muscular dystrophy (DMD), where seronegative patients were administered with high dose AAV, suggest that IgM formation could still cause significant immunotoxicities.88,89”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Patients receiving only corticosteroids had increased levels of IgM and IgG on days 5 and 7, respectively.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Salabarria et al. evaluated the kinetics and effects of immune modulation on complement activation in groups of patients who received high systemic doses of AAV989.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
In the citing paper
“Based on these findings, the authors proposed that in humans, the classical pathway is critical for the initiation of complement activation and the occurrence of associated pathologies/toxicities following high-dose systemic delivery of AAV, whereas the alternative pathway may serve as an amplification loop.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444 · cited 2×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 2×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“AAV exposure can trigger the complement system, an innate defensive mechanism that induces rapid destruction of pathogens and acts as a functional sensor of the surface area of invading particles (17–19).”
BackgroundImmune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788 · cited 1×
“The activation of the innate and adaptive immunologic responses after de novo exposure to AAV, as well as humoral and cellular responses to pre-existing host immunity, are some of the primary barriers to the expanded use of these therapies (8–10).”
BackgroundSelf-citationCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Self-citationComplement and Its Receptors: New Insights into Human Disease
Holers, V. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120154 · Cited by 430 · cited 1×
“The complement system is composed of more than 30 proteins that play important roles in recognition and elimination of pathogens (20).”
BackgroundDifferential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394 · cited 1×
“Importantly, Group 1 showed activation of the complement system, as demonstrated by reduction in C3 and C4, as well as increased C3a, C4a, C5a, Ba, Bb, and SC5b-9 AAV capsid proteins (alternative pathway) (8, 11, 21).”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357 · cited 1×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundZhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · cited 1×
“AAV particles are a potent activator of the innate immune system, not only through the physical properties of the capsid particle, but also through the response to the high capsid protein load associated with systemic AAV administration (11–13).”
BackgroundThe good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286 · cited 1×
“C5b binds to C6, C7, C8, and C9 to generate the soluble C5b-9 (SC5b-9) membrane attack complex (MAC), leading to cell lysis and cell death (17, 24).”
Background
Research works printed but not linked: 3
- Solid Biosciences Provides SGT-001 Program Update [press release]. 2019.
- Pfizer's New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study [press release]. 2020.
- Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease [press release]. 2020.
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“418 The collective evidence seems to suggest that complement activation in rAAV infusion occurs through the classical pathway.”
BackgroundCurrent clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 166
“…after dosing, 12 demonstrated AAV is shed in semen for a duration that is vector dose dependent, 10,13,14 and unmasked unexpected immunological responses to AAV that have been expanded in subsequent studies 5,6,15–21 and continue to pose safety and efficacy limitations to AAV gene therapy.”
Self-citationPhase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
Greenberg, B., Taylor, M. R. G., Adler, E. A., Colan, S. D., Ricks, D., Yarabe, P., Battiprolu, P. K., Shah, G., Patel, K., Coggins, M. P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2412392 · Cited by 112
Self-citationInnate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
“88,89 90 – 92 Clinical symptoms that may be related to complement activation included thrombotic microangiopathy (TMA), acute kidney injury involving atypical hemolytic uremic syndrome, thrombocytopenia, elevated transaminases, and endothelial injury.”
Self-citationSystemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Zhou, Y., Zhang, C., Xiao, W., Herzog, R. W., & Han, R. (2024) · Nature Communications · doi:10.1038/s41467-024-50569-6 · Cited by 60
“Encouragingly, a recent study from clinical trials showed that it is possible to prevent antibody response to AAV gene therapy by a cocktail of immune modulators (for example, rituximab plus sirolimus in addition to steroids) to prevent anti-AAV antibody formation 53 .”
Self-citationThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
Advances in the study and treatment of genetic cardiomyopathies
Parikh, V. N., Day, S. M., Lakdawala, N. K., Adler, E., Olivotto, I., Seidman, C. E., & Ho, C. Y. (2025) · Cell · doi:10.1016/j.cell.2025.01.011 · Cited by 51
Kachanov, A., Kostyusheva, A. P., Brezgin, S. A., Karandashov, I. V., Ponomareva, N. I., Tikhonov, A., Lukashev, A. N., Pokrovsky, V. S., Zamyatnin, A. A., Parodi, A., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22036 · Cited by 49
Smith, T. J., Elmore, Z. C., Fusco, R. M., Hull, J. A., Rosales, A., Martinez, M. L., Tarantal, A. F., & Asokan, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.004 · Cited by 45
“7,12,14 The recombinant enzymes IceM and IceMG described in this study offer immunomodulatory solutions that can directly address these challenges by transiently removing circulating as well as surface IgM, thereby reducing the risk associated with complement activation.”
Complement System Response to Adeno-Associated Virus Vector Gene Therapy
Kropf, E., Markusic, D. M., Majowicz, A., Mingozzi, F., & Kuranda, K. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.194 · Cited by 39
“The challenges associated with complement measurement and analysis are high-lighted in a recent publication from Salabarria et al. 66 In a retrospective analysis of 38 subjects across 4 AAV9-based gene therapy platforms, Salabarria et al. concluded that TMA following AAV gene transfer was CP driven…”
InfluentialAAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects
Chwalenia, K., Feng, V.-Y., Hemmer, N., Friedrichsen, H. J., Vorobieva, I., Wood, M. J. A., & Roberts, T. C. (2025) · Gene Therapy · doi:10.1038/s41434-025-00561-6 · Cited by 44
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B
Pipe, S. W., Miesbach, W., Recht, M., Leebeek, F. W. G., Key, N. S., Castaman, G., Lattimore, S., Coppens, M., Quellec, S. L., Mahajan, V., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2514332 · Cited by 41
Laforet, G. A. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.156 · Cited by 37
“28 AAV serotype LK03 in children with methylmalonic acidemia.”
InfluentialCosta-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58778-3 · Cited by 32
AAV vectors trigger DNA damage responses and STING-dependent inflammation in human CNS cells
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Alezz, M. A., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2024) · doi:10.21203/rs.3.rs-4171795/v1 · Cited by 32
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 32
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
“136 The administered doses required for effective treat-ment are typically high with the therapeutic modalities accumulating in the liver, and an increased risk of acute treatment-induced adverse events, including immune-mediated reactions, 135 when compared with localized treatments.”
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
Rana, J., Herzog, R. W., Muñoz-Melero, M., Yamada, K., Kumar, S. R. P., Lam, A. K., Markusic, D. M., Duan, D., Terhorst, C., Byrne, B. J., et al. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101216 · Cited by 26
“20,29,30 This combination is being tested for re-administration of AAV9 in gene therapy for Pompe disease and has also shown some positive outcomes for immune tolerance induction to FVIII protein in hemophilia A patients.”
BackgroundSelf-citationChauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05599-5 · Cited by 27
“These inflammatory responses can be further amplified by activation of the alternative complement pathway through direct interactions between complement component C3 and AAV capsid proteins [12].”
BackgroundStrategies for enhanced gene delivery to the central nervous system
Gao, Z. (2024) · Nanoscale Advances · doi:10.1039/d3na01125a · Cited by 29
Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors
Assaf, B. T. (2024) · Toxicologic Pathology · doi:10.1177/01926233241298892 · Cited by 26
“27 The study involved 38 individuals who received AAV9 and were divided into two groups based on their prophylactic immunomodulation regimens.”
InfluentialRetina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 25
Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application
Yin, L., He, H., Zhang, H., Shang, Y., Fu, C., Wu, S., & Jin, T. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70447 · Cited by 27
“Early recognition and intervention are crucial for improving patient outcomes, with monitoring of platelet counts, lactate dehydrogenase, haptoglobin, and renal function being essential [266].”
Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities
Maulana, T. I., Wevers, N. R., Kristoforus, T., Chandler, M. R., Lanz, H. L., Joore, J., Vulto, P., Villenave, R., Kustermann, S., Loskill, P., et al. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080621 · Cited by 24
Duan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 24
Self-citationByrne, B. J., Butterfield, R. J., Shieh, P. B., Smith, E. C., Licht, C. P. B., Binks, M. H., Casinghino, S. R., Delnomdedieu, M., Ravindra, K. C., McDonnell, T. G., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.032 · Cited by 19
Self-citationThrombotic Microangiopathy as an Emerging Complication of Viral Vector–Based Gene Therapy
Schwotzer, N., Sissy, C. E., Desguerre, I., Frémeaux‐Bacchi, V., Servais, L., & Fakhouri, F. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.04.024 · Cited by 22
Wang, X., Klann, P. J., Wiedtke, E., Sano, Y., Fischer, N., Schiller, L., Elfert, A., Güttsches, A., Weyen, U., Grimm, D., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450858 · Cited by 21
“…in elimination of the vector, also non-neutralizing AAV-binding antibodies can mediate undesired effects and lead to increased immune activation and liver toxicity and can contribute to complement activation and the development of thrombotic microangiopathies after systemic administration (30).”
InfluentialYang, R., Tran, N. T., Chen, T. J., Cui, M., Wang, Y., Sharma, T., Liu, Y., Zhang, J., Yuan, X., Zhang, D., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102563 · Cited by 18
“20 30 This concern has become more important, since recent trials have revealed significant safety concerns at doses exceeding 1E14 vg/kg. 31,32 Many approaches have been proposed to improve current AAV production systems.”
Maurizi, N., Ammirati, E., Silver, E., Hong, K., Bui, Q. M., Argirò, A., Olivotto, I., & Adler, E. D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.004 · Cited by 20
“4 For instance, TMA appears to be mediated by complement activation in the presence of high anti-capsid antibody titers, 6 yet the precise sequence of endothelial injury and platelet consumption is poorly characterized.”
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
Exploring the therapeutic potential of modulating nonsense-mediated mRNA decay
McMahon, M., & Maquat, L. E. (2024) · RNA · doi:10.1261/rna.080334.124 · Cited by 17
“High-dose AAV delivery has been shown to induce the presence of anti-AAV antibodies that pose significant problems (Smith et al. 2022), including the onset of thrombotic microangi-opathy as observed in DMD clinical trials (Salabarria et al. 2024).”
Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 17
“44 Complement activation pathways converge in the formation of the C5 convertase that produces C5a, a potent mediator of in fl ammation, and C5b, which initiates the formation of the membrane attack complex (MAC) mediating cell lysis and cell death.”
Hanlon, K. S., Cheng, M. L., Ferrer, R. M., Ryu, J. R., Lee, B., de la Cruz, D., Patel, N. J., Espinoza, P., Santoscoy, M. C., Gong, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.040 · Cited by 14
“4,22 Although immunosuppressive and modulatory regimens may mitigate some of these serious adverse events, 23 these pharmacological interventions are not without risk and may not be feasible or effective in all patients.”
Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer
Li, N., Kumar, S. R. P., Cao, D., Muñoz-Melero, M., Arisa, S., Brian, B. A., Greenwood, C. M., Yamada, K., Duan, D., & Herzog, R. W. (2024) · Viruses · doi:10.3390/v16101507 · Cited by 14
“Although AAV vectors elicit less innate immunity and are less efficient in activating CD8 + T-cell responses compared to many other vector systems, immune responses are nonetheless a major hurdle for AAV-based gene therapies, especially when given at high vector doses [14–18].”
BackgroundSelf-citationSherlock, S. P., Lévy, D., McIntosh, A., Shieh, P. B., Smith, E. C., McDonnell, T. G., Ryan, K. A., Delnomdedieu, M., Binks, M. H., Lal, A. K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.031 · Cited by 14
“35 He did have increasing hematocrit over several days, with a marked increase in left ventricular mass.”
Xicluna, R., Schwalie, P. C., Bell, E., von Tell, D., Steiner, G., Seeger, E., Heeren, J. J. F., Turksma, A. W., Pouw, R. B., Schwandt, T., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101551 · Cited by 16
“26 Complement inhibitors such as the C5 cleavage blocker eculizumab have been used to mitigate these toxicities and the use of the C3 inhibitor APL-9 is currently investigated.”
InfluentialImproving the safety of systemic viral gene therapy
McNally, E. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177078 · Cited by 14
“Notably, the authors cataloged data from 38 children who received several different gene therapy protocols and collated the information at a single center (2).”
InfluentialMuñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
Minno, G. D., Miesbach, W., Castaman, G., & Peyvandi, F. (2024) · Haematologica · doi:10.3324/haematol.2023.284622 · Cited by 21
Emami, M. R., Brimble, M. A., Espinoza, A., Owens, J. M., Whiteley, L. O., Casinghino, S. R., Lanz, T. A., Farahat, P. K., Pellegrini, M. A., Young, C. S., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101349 · Cited by 14
“3 In our study, TMA was observed in one participant, subject 5; however, pre-dose screening did not reveal the presence of positive anti-AAV9 titers in this subject at baseline (Figure 1).”
Wolff, J. M., Capocci, N., Atas, E., Bharucha-Goebel, D. X., Brandsema, J. F., Butterfield, R. J., Chadwick, C. B., Corti, M., Crawford, T. O., Cripe, L. H., et al. (2025) · Neuromuscular Disorders · doi:10.1016/j.nmd.2025.106208 · Cited by 14
Self-citationAtypical hemolytic uremic syndrome
Walsh, P. R., & Kavanagh, D. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.05.010 · Cited by 14
Benemei, S., Gatto, F., Marcucci, R., & Gresele, P. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2413-4345 · Cited by 11
“40”
InfluentialHordeaux, J., Lamontagne, J., Bandyopadhyay, S., Bell, P. L., Wilson, J. M., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.017 · Cited by 10
Iroanya, G. I., Subramanyam, P. N., Wells, K. D., & Green, J. A. (2025) · Human Gene Therapy · doi:10.1177/10430342251378524 · Cited by 11
“83 Beyond enzymatic approaches, pharmacologic immuno-suppression remains a widely used strategy to dampen innate immune responses and enhance vector ef fi cacy.”
Fuchs, S. P., Mondragon, P. G., Zabizhin, R., Tomer, S., Wang, L., Cook, E., Dudley, D. M., Weisgrau, K. L., Furlott, J. R., Coonen, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63970-6 · Cited by 10
“In a recent clinical trial, the combined use of rapamycin and rituximab signi fi cantly reduced the magnitude of anti-capsid antibodies following AAV9 gene transfer 60 .”
Immune Toxicities in AAV Gene Therapy: Overview for Clinicians
Parajuli, S., Gallagher, T. L., & Flotte, T. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073196 · Cited by 12
“…of immune-mediated toxicity were investigated in a study by Salabarria et al. linking complement-mediated thrombotic microangiopathy (TMA) to high-dose rAAV exposure in both clinical trials and approved therapies like Zolgensma (the lowest reported dose that has triggered TMA is 1 × 10 13 ) [54].”
Developing AAV-delivered nonsense suppressor tRNAs for neurological disorders
Wang, J., Gao, G., & Wang, D. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00391 · Cited by 10
“Recent studies suggested that immunomodulation [121,122] and antibody-cleaving enzymes [123 – 125] could be viable strategies to enable rAAV re-dosing.”
BackgroundCheng, M. L., de la Cruz, D., Crain, A. V., Espinoza, P., Ng, C., Elmore, Z. C., Asokan, A., & Maguire, C. A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101407 · Cited by 11
Nonclinical strategies and considerations to enable the redosing of gene therapies
Moffit, J. S., Alatsis, K. R., Blanset, D. L., Buss, N. A. P. S., & Rana, P. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101520 · Cited by 10
Lek, A., Atas, E., Lin, B. L., Hesterlee, S. E., Abbott, J. K., Byrne, B. J., & Bönnemann, C. G. (2024) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-240002 · Cited by 10
“…(B-cell depletion) and sirolimus (inhibits B-cell proliferation, downregulates cytotoxic T-cells) prevents the humoral response to AAV capsid and enhances safety and efficacy, allowing for repeat dosing and preventing immune responses to the transgene in null mutations (CRIM-negative) [36].”
Self-citationIs Duchenne gene therapy a suitable treatment despite its immunogenic class effect?
Tang, A., & Yokota, T. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2447072 · Cited by 10
“Following the systemic administration of AAV vectors, complement-mediated thrombotic microangiopathy (TMA), kidney injury, liver toxicity, and myocarditis have been observed [107].”
Clinical gene therapy restores hearing: a paradigm shift
Han, S., Chen, Z., Wang, D., Jiang, L., Fan, X., Zhong, J., Cui, C., Chen, Y., lv, J., Zhang, J., et al. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.07.007 · Cited by 8
Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies
Doshi, B. S., Markmann, C., Novak, N. C., Rojas, S. J., Davidson, R. J., Chau, J. Q., Wang, W., Carrig, S., Rus, C. M., Samelson‐Jones, B. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.003 · Cited by 9
“As AAV-IgM complexes could trigger complement responses and subsequent toxicity, 69,70 the ability to clear IgM in addition to IgG may provide additional clinical bene fi t.”
Mehta, N., Gilbert, R., Chahal, P. S., Moreno, M., Nassoury, N., Coulombe, N., Gingras, R., Mullick, A., Drouin, S., Sasseville, M., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00524-x · Cited by 10
“The use of systemically-delivered high vector doses has resulted in anti-AAV capsid CTL-mediated toxicity, including thrombotic microangiopathy in spinal muscular atrophy and Duchenne muscular dystrophy patients [5].”
Araujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7
“45 The already-mentioned study by Smith and colleagues also reported uptake of AAV vectors into various cell types present in the blood, with neutrophils and moDCs showing the highest level, followed by monocytes, cDC, and pDC. 42 The uptake of AAV vectors into cDC triggered their activation, as…”
Molina, E., Tejero, M., Duzenli, O. F., Kuoch, H., Caine, C., Krotova, K. Y., Paulaitis, M. E., & Aslanidi, G. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101358 · Cited by 8
Warrington, S., Hoang, T. T., Seirup, M., Abdelhamid, L., Saha, H., Bing, S. J., Saleh, S., Phue, J., & Mazor, R. (2025) · Gene Therapy · doi:10.1038/s41434-025-00528-7 · Cited by 7
“These preexisting antibodies can also form immune complexes and induce antibody mediated complement activation that has been proposed to contribute to various toxicities [6, 7].”
The clinical toxicity of advanced therapy medicinal products
Henderson, F. J. H., & Hill, S. L. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70104 · Cited by 6
“57 This response can be exacerbated by pre-existing anti-AAV antibodies or genetic predisposition, as seen in a fatal case following SMN AAV9 gene therapy in a child with complement factor I gene mutations.”
Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products
Mann, C. J., Giblin, J., Braun, M., Schmid, F., Sørensen, M. R., Caferra, P., Hudák, A., Letoha, T., Coderch, N., Hickling, T. P., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102422 · Cited by 7
“93,94 Regulatory guidelines refer to possible requirements for complement assessment in preclinical studies (e.g., EMA/CAT/80183/2014; Table S1), but there are no clear clinical recommendations.”
Leon‐Astudillo, C., Salabarria, S. M., Chadwick, C. B., Zingariello, C. D., Berthy, J., Prascak, J., Shifflet, J., Killian, G. M., Corti, M., Shoemaker, L. R., et al. (2026) · Journal of Neuromuscular Diseases · doi:10.1177/22143602261424971 · Cited by 8
“3,22,24,31 The doses required to achieve this therapeutic range was well tolerated overall, although trough levels were higher at times primarily due to limited availability of the liquid formulation for dose adjustments.”
InfluentialSelf-citationZhao, Q., Yu, S., Fu, D., Wu, Z. F., Zhou, J., Yang, Y., Chen, C., Wu, N., Wang, Y., Xi, W., et al. (2025) · Virus Research · doi:10.1016/j.virusres.2025.199549 · Cited by 6
Gene therapy in neuronopathic lysosomal storage disorders
Donald, A., Horgan, C., López, M. J. D. C., Jones, S., & Wynn, R. F. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.05.010 · Cited by 7
Abdelhamid, L., & Mazor, R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01127-5 · Cited by 7
“Though the exact complement activation pathway in AAV remains uncertain, evidence shows complement activation after AAV dosing, with clinical trials highlighting serious complications such as thrombotic microangiopathy (TMA) and renal failure, particularly with high systemic AAV doses (31, 59, 60).”
Levart, T. K., Kar, N. O., Pegan, C. M., Vrščaj, E., Gergeli, A. T., Loboda, T., & Osredkar, D. (2025) · Case Reports in Nephrology and Dialysis · doi:10.1159/000546114 · Cited by 5
“The study by Salabarria [12] suggests that TMA in the setting of AAV gene therapy is antibody dependent (classical pathway) and ampli fi ed by the alternative complement pathway, and patients receiving prophylactic immunosuppressive treatment (rituximab and sirolimus) did not have a signi fi cant…”
Tsaregorodtseva, T. S., Radyukhina, M. A., Ayupova, A. I., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114818 · Cited by 5
“As a result, Group 2 showed no significant increase in IgM or IgG antibodies against AAV9, exhibited minimal complement activation, and did not develop TMA, whereas Group 1 experienced a robust humoral response and complement-mediated TMA [133].”
Efficient LAMA1 Gene Activation by Epigenome Editing as a Therapeutic Approach for LAMA2-CMD
Qin, Y., Akbulut, T., Mandraju, R., Connolly, K., Bechill, J., Assadian, F., Foster, C., Shottek, A., Levy, S., Benoit, J. D., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342251401873 · Cited by 6
“19 Similar combinations of immuno-suppressive agents can be used prophylactically to control the initial wave of immune response and to induce transgene-speci fi c immune tolerance.”
Tavakolidakhrabadi, N., Ding, W. Y., Welsh, G. I., & Saleem, M. A. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf332 · Cited by 4
“Notably, high systemic doses of AAV have been associated with thrombotic microangiopathy in other clinical contexts ( e.g. spinal muscular atrophy trials) [183 ,184 ].”
Immunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 6
“In the case of AAVs, AAV9 has been shown to initiate both the classical and alternative pathways leading to thrombotic microangiopathy in the clinic [26].”
Safety of in vivo gene therapy in children: mechanisms and management of liver injury
Jeyaraj, R., Brown, L. K., Jagadisan, B., Muntoni, F., Baruteau, J., Gupte, G. L., Breuer, J., Gissen, P., Oo, Y. H., & Dhawan, A. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00380-3 · Cited by 5
Bedoyan, J. K., Morgan, T., Sun, A., Li, H., Gruskin, D. J., Payton, M., Chereau, F., Swenson, E. S., Lin, Q., Kay, M. A., et al. (2026) · Gene Therapy · doi:10.1038/s41434-026-00609-1 · Cited by 4
Genetic Medicine for Danon Disease
McNally, E. M., & Spencer, M. J. (2025) · New England Journal of Medicine · doi:10.1056/nejme2415793 · Cited by 4
Lu, Q. L., Zhao, S., & Blaeser, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.051 · Cited by 3
Pham, Q. H., Bheemsetty, V. A., Nguyen, P. A., Samara-Kuko, E., Gao, F., Chuah, M., & VandenDriessche, T. (2025) · Human Gene Therapy · doi:10.1177/10430342251359989 · Cited by 3
“17,39 In this study, we have validated novel combinations of muscle-targeted CRE arrays that resulted in improved vector performance in a preclinical mouse model of Pompe disease.”
Currier, M. A., Reha, A., Hutzen, B. J., Wang, P.-Y., Chen, C., Glaspell, A. M., Paudel, S. N., Venkataramany, A. S., Das, D., Hanlon, D., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101541 · Cited by 3
“27 Finally, we point out that recent experience suggests that blinatumo-mab may be able to substitute for intensive chemotherapy, as determined in a real-world experience in acute lymphoblastic leukemia patients who were unable to tolerate or were resistant to conventional chemotherapy.”
Saha, M., Bhake, R., Meyers, C., Coleman, K. E., Trivedi, P. D., Gallman, M., Biswas, M., Herzog, R. W., Byrne, B. J., & Corti, M. (2025) · Human Gene Therapy · doi:10.1177/10430342251385586 · Cited by 6
Self-citationXu, R., Diep, T., Singh, K., Bakshi, S., Wu, G. F., Lu, M., Tang, G., Schwerk, J., Sun, Q., Häberle, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.045 · Cited by 3
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 5
Zhou, X., Wang, Z., Liao, W., Yin, Q., Xiong, C., Zheng, Y., & Peng, W. (2024) · CytoJournal · doi:10.25259/cytojournal_153_2024 · Cited by 3
“29-32] The TNF (ligand) superfamily member 5 (CD154) can exist in platelets, and when platelets are activated, CD154 molecules can be released.”
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design
Satish, T., Hong, K. N., Kaski, J. P., & Greenberg, B. H. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.024 · Cited by 3
AAV vector immunotoxicity: Stopping the domino effect
Asokan, A. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.016 · Cited by 3
AAV vectors advance cardiac gene therapy while overcoming challenges.
Muramatsu, S. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131704 · Cited by 3
Flotte, T. R., Blackwood, M., Arjomandnejad, M., Harkins, A. L., Sylvia, K., Iyer, S., Kokoski, D., Artinian, R., & Keeler, A. M. (2025) · medRxiv · doi:10.1101/2025.05.07.25327170 · Cited by 3
Chopping down antibodies for a good cause
Biswas, M., & Herzog, R. W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.007 · Cited by 2
Self-citationLatest Developments in Gene Therapy for Heart Failure
Olandt, C. A., Kelso, C., Hong, K. N., & Greenberg, B. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01066-y · Cited by 2
“Its peak effects usually occur within 4–14 days after GTT administration [84].”
Thrombotic microangiopathy following gene therapy for 5q-spinal muscular atrophy
Camelo, C. G., Mendonça, R. D. H., Moreno, C. A. M., Ferreira, J. C. O. A., Ortega, A., van der Linden, V., Campos, R. S. M., van der Linden, H., da Cunha, N. S. C., Gurgel‐Giannetti, J., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00545-6 · Cited by 2
“The atypical presentation of the viral vector to the host immune system — characterized by a peak concentration within one hour of infusion and extensive body-wide exposure — accelerates the humoral immune response [35].”
Maurizi, N., Hong, K. N., Silver, E., Patel, U., & ADLER, E. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.340 · Cited by 6
ALT/CK Ratio as an Early Marker of Liver Injury After Gene Therapy in Duchenne Muscular Dystrophy
Drakou, E., Needum, C., Konst, K., Chagat, S., Abraham, R. S., Weymann, A., & Flanigan, K. M. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074192 · Cited by 2
Xicluna, R., Yamada, K., Gonzalez-Visiedo, M., Greenwood, C. M., Zaugg, D., Waiz, D., Steiner, G., Hahn, K., Schwandt, T., Otteneder, M. B., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.014 · Cited by 2
Self-citationKornegay, J. N., Stedman, H. H., Lawlor, M. W., Byrne, B. J., & Childers, M. K. (2024) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2024.28 · Cited by 3
Self-citationA Tool to Eliminate IgM Immunoassay Interference
Pöhler, A., Wessels, U., Staack, R. F., Nordgren, M., Lood, R., & Stubenrauch, K. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01067-0 · Cited by 2
Redosing of AAV vectors in the brain after intracranial injections: Low-ish hanging fruit?
Maguire, C. A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101469 · Cited by 2
Timing and Implementation of Viral Gene Therapy for Cardiomyopathy
McNally, E. M. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.01.020 · Cited by 2
Santoscoy, M. C., Espinoza, P., Hanlon, K. S., Yang, L., Nieland, L., Ng, C., Badr, C. E., Hickman, S. E., de la Cruz, D., Griciuc, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.25.614546 · Cited by 2
The Responsible Development of Adeno-Associated Virus Gene Therapies
Wilson, J. M., & Caplan, A. L. (2025) · Human Gene Therapy · doi:10.1177/10430342251359668 · Cited by 2
Selective IgM digestion improves anti-AAV IgG detection in the immune complex assay format
Wessels, U., Pöhler, A., Ros, F., & Stubenrauch, K. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2548191 · Cited by 1
“Moreover, anti-AAV IgM often co-exist with anti-AAV IgG [6], making anti-AAV IgM interference practically relevant for monitoring of the immune response to gene therapy.”
Translational progress in the development of pharmacotherapies for Duchenne muscular dystrophy
Swiderski, K., & Lynch, G. S. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2571355 · Cited by 2
Top stories on cardiac gene therapy delivery
Bianan, R. M., Pinto, Y. M., & Creemers, E. E. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2025.10.041 · Cited by 1
Metadata
- Authors
- Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., Leon-Astudillo, C., Tavakkoli, F., Kirn, D. H., Schwartz, J. D., & Byrne, B. J.
- Affiliations
- University of Florida Health (US)
- National Institutes of Health (US)
- Indiana University South Bend (US)
- Corresponding author
- Byrne, Barry J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2024-01-02
- Volume
- 134
- Issue
- 1
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10760971
- OpenAlex
- W4388860142
- Cited by
- 159
- References
- 35
- Citations by year
- 2026: 59 · 2025: 55 · 2024: 44
- FWCI
- 26.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- College of Medicine, University of Florida (HD052682)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- thrombotic microangiopathy, AAV9, AAV gene therapy, complement activation, classical complement pathway, alternative complement pathway, rituximab, rapamycin, corticosteroids, immunomodulation, D-dimer, atypical hemolytic uremic syndrome, immune-mediated toxicity
- MeSH terms
- Dependovirus, Humans, Immunoglobulin G, Immunoglobulin M, Thrombotic Microangiopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.